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Introduction
Anaplastic large cell lymphoma (ALCL) is a subtype of T-
cell non-Hodgkin’s lymphoma characterized by marked cellu-
lar pleomorphism, a propensity to grow cohesively, and a ten-
dency to colonize lymph node sinuses. ALCL have a unique
immunophenotype expressing high levels of CD30, cytotoxic
granules (i.e. granzyme and perforin), and often lack T-cell
associated/restricted antigens.1 The World Health
Organization (WHO) classification of lymphoid malignancies
recognizes two systemic forms of ALCL, defined by the pres-
ence or the absence of chromosomal translocations involving
the anaplastic lymphoma kinase (ALK) gene at the 2p23
locus.2 The most common translocation is the t(2;5)(p23;q35)
that codes for the nucleophosmin (NPM)-ALK fusion protein.3
All ALK translocations invariably result in constitutively
active ALK chimeric proteins, which lead to the consequent
activation of several growth-promoting and anti-apoptotic
pathways, including PI3K/AKT/mTOR, JAK/STAT3,
RAS/ERK, and others.4 Among them, it is known that the con-
stitutive activation of the transcription factor STAT3 is strictly
required for the maintenance of the ALK-mediated pheno-
type.5-8 Loss of STAT3 signaling in ALK+ ALCL results in cell
cycle arrest, followed by the execution of an irreversible pro-
gram of apoptosis.9,10 This phenomenon is associated with the
modulation of a large number of genes, suggesting that the
oncogenic activity of ALK+ ALCL cells requires STAT3-medi-
ated transcription.10 Accordingly, a class-prediction analysis of
ALCL expression profiles identified a STAT3 signature as a
positive predictor for systemic ALK+ ALCL.10
The pleiotropic effects of STAT3 are due to the concomitant
activation/repression of multiple sets of genes, which control
crucial functions, such as cell cycle, apoptosis, DNA damage,
adhesion, motility, G protein signaling, inflammation,
immune response, metabolic pathways, and angiogenesis.11
STAT3 mediates the enhanced transcription of both anti-
apoptotic factors and cell cycle regulators, such as Bcl-XL, sur-
vivin, cyclin D3, C/EBPβ, Mcl-1 and others, providing prolif-
erative and survival signals in ALK+ ALCL cells.5,7,12-14
Moreover, STAT3 controls the expression of molecules that
determine T-cell identity and signaling, and is in part respon-
sible for the “null” phenotype of ALK+ ALCL.15 The strict
requirement for STAT3 in ALK+ ALCL makes this molecule an
ideal therapeutic target, particularly in the perspective of
acquired resistance to ALK inhibitors.16,17 Transcription factor
have been traditionally considered “undruggable” because the
design of small and selective molecules that disrupt protein-
protein or protein-DNA interactions bears considerable chal-
lenges. However, decoys targeting STAT3 have been success-
fully employed in vivo,18 and encouraging data are also emerg-
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Systemic anaplastic large cell lymphoma is a category of T-cell non-Hodgkin’s lymphoma which can be further sub-
divided into two distinct entities (ALK+ and ALK–) based on the presence or absence of ALK gene rearrangements.
Among several pathways triggered by ALK signaling, constitutive activation of STAT3 is strictly required for ALK-
mediated transformation and survival. Here we performed genome-wide microRNA profiling and identified 48
microRNA concordantly modulated by the inducible knock-down of ALK and STAT3. To evaluate the functional
role of differentially expressed miRNA, we forced their expression in ALK+ anaplastic large cell lymphoma cells, and
monitored their influence after STAT3 depletion. We found that the expression of the microRNA-17~92 cluster par-
tially rescues STAT3 knock-down by sustaining proliferation and survival of ALK+ cells. Experiments in a xenograft
mouse model indicated that forced expression of microRNA-17~92 interferes with STAT3 knock-down in vivo. High
expression levels of the microRNA-17~92 cluster resulted in down-regulation of BIM and TGFβRII proteins, sug-
gesting that their targeting might mediate resistance to STAT3 knock-down in anaplastic large cell lymphoma cells.
We speculate that the microRNA-17~92 cluster is involved in lymphomagenesis of STAT3+ ALCL and that its inhi-
bition might represent an alternative avenue to interfere with ALK signaling in anaplastic large cell lymphomas.
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ABSTRACT
ing with small molecules such as S3I-201, niclosamide and
pyrimethamine.11,19
An alternative strategy to interfere with key pathways
linked to cancer progression was provided by the discov-
ery that non-coding RNA, such as micro-RNA (miRNA,
miR), could simultaneously target multiple oncogenes.
Consequently, the manipulation of miRNA was intended
as a “combination” therapy to impair compensatory
mechanisms and feedback loops limiting the effectiveness
of standard therapies, or responsible for the development
of resistance.20
miRNA are a class of evolutionarily conserved noncod-
ing RNA of 18-22 nucleotides that modulate gene expres-
sion through canonical base pairing between the seed
sequence of the miRNA and its complementary match
sequence present mainly within the 3’-UTR of target
mRNA.21 It is known that miRNA can inhibit the expres-
sion of target mRNA either by mRNA cleavage or by
translational repression.22 Deregulated miRNA have been
observed in many cancers, displaying either tumor sup-
pressor (miR-26a, miR-34a) or oncogenic functions (miR-
21, miR-17~92 cluster, miR-155).23 Recent studies identi-
fied a number of miRNA aberrantly expressed in ALCL
patients and suggested the involvement of miR-101,24
miR-29a,25 miR-135-b,26 and miR-1627 in mediating the
oncogenic ALK signaling. 
Here, we performed genome-wide profiling of STAT3-
regulated miRNA in ALK+ ALCL cell lines. Microarray data
analysis revealed a series of miRNA concordantly modu-
lated by ALK and STAT3 knock-down (KD). Specifically,
we found that the forced expression of miR-17~92 cluster
promotes the survival of ALK+ ALCL cells in low serum
conditions and partially rescues the STAT3 KD phenotype
in vitro and in vivo. These data suggest that the miR-17~92
cluster could sustain oncogenic properties of STAT3 in T-
cell lymphoma and that its inhibition could interfere with
ALK downstream signaling.
Methods
Cell lines and culture
Human ALCL cells TS-SUP-M2, JB-6, L82, and Karpas-299 were
cultured under standard conditions in RPMI-1640 (Sigma-Aldrich,
St Luis, MO, USA) supplemented with 10% fetal calf serum
(Lonza, Rockland, ME, USA), 2 mM glutamine, 100 U/mL peni-
cillin and 100 mg/mL streptomycin (Eurobio Biotechnology, Les
Ulis, France). TS-SUP-M2-A5, TS-SUP-M2 A5M, TS-SUP-M2 S3S
(inducible cell lines derived from TS-SUP-M2), and JB6 S3S were
generated, as described elsewhere.10,12 Human HEK-293T cells
(ATCC, Manassas, VA, USA) were cultured in DMEM medium
with identical supplements and conditions.
Plasmid constructs, transfection and lentiviral 
production
The empty vector [pCCLsin.cPPT.hEF1a (intron with MCS)
deltaLNGFR.Wpre], miR-223 (intronic pri-mir 223), and miR-142
(intronic murine pri-mir 142) expressing plasmids were kindly pro-
vided by Dr. Naldini. miR-34a, miR-17~92 and miR-17~92inv
were cloned in pCCLsin vector. The pTRIPZ- miR-17~92 sponge
construct was kindly provided by Dr Fu.28 Transfection of HEK-
293T cells was performed with Effectene (Qiagen, Valencia, CA,
USA). High titer lentiviral stocks were produced as previously
described.5,7,12-14 Aliquots of virus were used to infect exponentially
growing cells (1x105/mL) in the presence of 8 mg/mL of polybrene.
The infectivity was determined (after 96 h) by real time quantita-
tive polymerase chain reaction (RT-qPCR) analysis of miRNA. 
MicroRNA expression profiling
TS-SUP-M2-A5, TS-SUP-M2-A5M and TS-SUP-M2 S3S were
treated with doxycycline (1 mg/mL) to induce short hairpin
(sh)RNA expression, and monitored for green fluorescent protein
(GFP) expression by FACS analysis. STAT3 and ALK KD were
monitored by western blotting. Total RNA was isolated at indicat-
ed time points from two independent replicates, using Trizol
Reagent (Life Technologies, Inc., Rockville, MD, USA). RNA sam-
ples were hybridized on a human miRNA microarray (#G4470B,
Agilent Technologies, Palo Alto, CA, USA), as described else-
where.29 An Agilent scanner and Feature Extraction 10.5 software
(Agilent Technologies) were used to obtain the raw microarray
data. Microarray results were analyzed using GeneSpring GX 10
software (Agilent Technologies). Data transformation was applied
to set all negative raw values at 1.0, followed by a quantile normal-
ization. A filter on low gene expression was used to keep only the
probes expressed in at least one sample. Differentially expressed
genes were selected to have a 1.5-fold expression difference
between  late time points after KD (84/96 h for ALK and 120/140
h for STAT3) and controls (untreated cells) and a statistically sig-
nificant P-value (<0.05) using an unpaired t-test with Benjamini-
Hochberg correction. Differentially expressed genes were
employed for cluster analysis of samples using the Manhattan cor-
relation as a measure of similarity.  
Tumor growth in immunocompromised mice
TS-SUP-M2 S3S cells (5×104) were injected subcutaneously in
matrigel into the rear flanks of 24 NOD/SCID/IL2Rg-/- (NSG) mice
(Charles River Laboratories) divided into three groups: UTR,
17~92, and 17~92inv. Tumor growth was monitored over time by
determining the diameter of tumor masses. Two weeks after injec-
tion of the cells, six mice in each group were treated with 0.1
mg/mL doxycycline in a 0.5% sucrose solution in light-proof bot-
tles, refreshed every 4 days. After 24 days of doxycycline treat-
ment, mice were sacrificed and tumors were excised. Animals
were housed in the animal facility of the University of Turin and
treated in accordance with guidelines approved by the local Ethical
Animal Committee.
Results
STAT3-dependent microRNA signature in ALK-positive
anaplastic large cell lymphoma cells    
Using inducible KD approaches in ALK+ ALCL cell lines,
we recently demonstrated that the ALK expression signa-
ture largely depends on the transcriptional activity of
STAT3.10,12 To identify oncogenic miRNA involved in ALK+
ALCL, we performed genome-wide miRNA expression
profiling in the ALK+ ALCL cell line TS-SUP-M2, following
ALK (A5) or STAT3 (S3S) inducible KD. Experiments were
carried out at different time points (72, 84, 96, 120, and
144 h), based on the kinetics of the doxycycline-mediated
decline of ALK and STAT3 protein levels (Figure 1A,B). As
controls, we used untreated cells and TS-SUP-M2 cells
expressing a non-functional shRNA construct (A5M).12 A
total of 24 samples from two independent replicates were
hybridized to Agilent G4470B gene chips, which represent
723 human miRNA. Data analysis revealed detectable
expression of 205 miRNA, of which 60 resulted signifi-
cantly regulated by ALK KD and 27 by STAT3 KD
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(P<0.05), with 14 overlapping miRNA (Online
Supplementary Figure S1A). Differential analysis identified
48 miRNA concordantly modulated in ALK and STAT3
KD samples, as compared to controls. Hierarchical clus-
tering of samples according to the differentially expressed
miRNA generated a dendrogram with three major
branches sorting out controls, early, and late KD samples,
independently of ALK or STAT3 silencing (Figure 1C). A
tool for annotations of human miRNA30 recognized
enrichment of specific miRNA families, such as miR-17, -
106a, -181, -193b, -143, and -221 clusters (Figure 1D). It is
noteworthy that miR-223, miR-100, and miR-34a were
significantly up-regulated, while the miR-17-92 cluster
was down-regulated by STAT3 KD (Figures 1C,D and
2A,B). The ALK/STAT3-dependent miRNA signature was
further confirmed by RT-qPCR in TS-SUP-M2 (Figure
2C,D) and in JB-6 cells. Specifically, 24 out of 34 miRNA
resulted accordingly modulated by STAT3 KD in JB-6 and
SUP-M2 cells (Online Supplementary Table S1). To validate
the ALCL miRNA signature obtained by gene silencing,
and to exclude shRNA-induced off target effects, we
took advantage of a highly potent and selective ALK
inhibitor (CEP-28122).31 miRNA expression profiling of
TS-SUP-M2 cells treated with control diluent or CEP-
28122 (200 nM) for 12 h identified 109 mirRNA with a
fold-change >1.5. Among these, a significant number of
E. Spaccarotella et al.
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Figure 1. (A-B) Kinetics of ALK and STAT3 knock-down (KD) in the ALK-positive ALCL cell line TS-SUP-M2. (A) TS-SUP-M2 cells co-transduced
with pLV-tTR-KRAB/DsRed and pLVTH-ALK-A5/GFP (A5) or with the mutated pLVTH-ALKA5M/GFP (A5M) lentiviral preparations were cultured
in the presence (+ Doxy) or absence (- Doxy) of doxycycline (1 mg/mL) and harvested at the indicated times. Whole-cell lysates were analyzed
by western blotting with anti-α-tubulin or ALK antibodies. (B) Two clones (2X and 21) derived from TS-SUP-M2 cells co-transduced with pLV-
tTR-KRAB/DsRed and pLVTH-STAT3-S3S/GFP (S3S) lentiviral preparations were cultured in the presence (+ Doxy) or absence (- Doxy) of doxy-
cycline (1 mg/mL) for the indicated time intervals and analyzed by western blotting with anti-α-tubulin or STAT3 antibodies. (C) Heatmap rep-
resentation of miRNA modulated by ALK or STAT3 inducible KD in TS-SUP-M2 cells. Light blue and yellow lanes designate ALK- and STAT3-
silenced samples, respectively. RNA samples from two independent replicates were hybridized on a human miRNA microarray (#G4470B,
Agilent Technologies). Differentially expressed miRNA were employed for sample cluster analysis using the Manhattan correlation as a meas-
ure of similarity.  Expression levels are referred to control samples. Upregulated miRNA are shown in red, downregulated  miRNA are shown
in green. A5M, A5, and S3S indicate  control, ALK, or STAT3 shRNA, respectively. (D) miRNA concordantly modulated by ALK or STAT3 KD.
miRNA clusters are highlighted by the same color. FC: fold change after STAT3 KD (late time points vs. controls); P value: P value of an unpaired
t-test with Benjamini-Hochberg correction; regulation: direction of miRNA expression modulation after STAT3 KD. 
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miRNA overlapped with those identified by the ALK (25
out of 60) or ALK/STAT3 (20 out of 48) signatures (Online
Supplementary Figure S1B).
Expression of the miR-17~92 cluster partially rescues
STAT3 knock-down  in anaplastic large cell 
lymphoma cells
To establish the role of deregulated miRNA in ALCL
pathogenesis, we first sought to examine the effects of sta-
ble expression of miR-34a, miR-223, and the miR-17~92
cluster on in vitro cell growth. Empty vector and miR-142,
which was not deregulated in our ALCL model system,
were used as controls. Lentiviral-mediated expression of
miR-34a, miR-223, and the miR-17~92 cluster had no sig-
nificant effects on cell proliferation or survival of ALK+
ALCL cell lines (TS-SUP-M2 and JB-6), in standard cell cul-
ture conditions (Online Supplementary Figure S2). To study
whether the indicated miRNA could modify the sensitivi-
ty of ALCL cells to stress conditions, we treated miRNA-
transduced TS-SUP-M2 cells with increasing concentra-
tions of doxorubicin, ALK inhibitors, or with a suboptimal
supplement of fetal calf serum (Online Supplementary Figure
S3). In the low serum concentration (2%), TS-SUP-M2
cells expressing miR-34a and miR-223 displayed a progres-
sive increment of apoptotic cells, comparable to controls
(data not shown). In contrast, miR-17~92 over-expression
significantly decreased the basal level of cell death (Online
Supplementary Figure S3C). Accordingly, miR-17~92 trans-
duced cells displayed higher metabolic activity, as meas-
ured by ATP production (Online Supplementary Figure S3D).
These results prompted us to focus on the miR-17~92
cluster, a known oncogenic miR,32 previously demonstrat-
ed to be highly expressed in systemic ALK+ ALCL.24 To
confirm STAT3–dependent regulation of the miR-17~92,
JB-6, L82, and Karpas-299 ALK+ ALCL cells were treated
with increasing concentrations of the STAT3 inhibitor
Stattic.33 RT-qPCR of miR-19a and miR-92 indicated that
pharmacological inhibition of STAT3 dose-dependently
decreased miR-17~92 cluster expression in all cell lines
(Online Supplementary Figure S4). 
To evaluate the functional role of the miR-17~92 cluster
in ALK+ ALCL cells, we transduced TS-SUP-M2 S3S cells
with lentiviral particles expressing miR-17~92 cluster
(17~92), an antisense construct (17~92inv), or an empty
vector (EV) as negative controls, and monitored the changes
on proliferation and survival after inducible KD of STAT3
(Figure 3A). miR-17~92 over-expression was first confirmed
by RT-qPCR measuring the mature forms of miR-19a and
miR-92, at 96 h post-transduction (Figure 3B, and data not
shown). Doxycycline treatment of TS-SUP-M2 S3S cells
resulted in a significant and reproducible down-regulation
of STAT3 protein expression at day 5 (Figure 3C). Kinetics
of cell death induced by conditional STAT3 KD revealed
that the rates of apoptosis were significantly lower in TS-
SUP-M2 S3S cells expressing miR-17~92 cluster than in
controls (Figure 3D). These data were further confirmed in
a parallel experiment performed in JB-6 S3S cells (Online
Supplementary Figure S5). Overall these findings indicate that
miR-17~92 partially rescued the STAT3 KD phenotype.
To corroborate the specificity of the effects of the miR-
miR-17~92 cluster sustains the ALCL phenotype
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Figure 2. Expression levels of representative miRNA in TS-SUP-M2 cells. Quantification of the miR-17~92 cluster (A) and miR-223 (B), as
revealed by genome-wide miRNA profiling following ALK or STAT3 inducible KD. Relative quantities are log2 normalized to control samples.
The error bars report standard deviations from duplicates.  (C-D) Validation of ALK/STAT3-mediated miR-19a and miR-223 regulation by RT-
qPCR. Changes of mature miR-19a and miR-223 levels, normalized to RNU6B expression, were measured at the indicated time points after
doxycycline treatment in an independent experiment. Relative quantities are log2 normalized to control samples. 
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17~92 cluster, we analyzed the functional changes of
reducing miR-17~92 by a doxycycline-inducible sponge
construct that sequesters the corresponding miRNA.28
Expression of miR-17~92 sponge lentiviral construct
increased cell death of TS-SUP-M2 S3S cells upon doxycy-
cline administration, thus reverting the effects of the miR-
17~92 cluster (Online Supplementary Figure S6).
To assess whether forced expression of miR-17~92
interferes with STAT3 KD in vivo, we studied the growth
patterns of subcutaneously transplanted TS-SUP-M2 S3S
cells, transduced with either the miR-17~92 cluster or the
antisense construct as a control. TS-SUP-M2 S3S cells,
injected subcutaneously into the flanks of NSG mice,
formed visible tumors 2 weeks after injection. In control
mice treated with doxycycline (UTR+), tumor masses
gradually diminished compared with those in untreated
mice (UTR-). In contrast, miR-17~92 over-expressing
tumors underwent a minor growth regression upon
STAT3 KD, and eventually resumed growth within 2
weeks of doxycycline treatment (Figure 3E). miR-17~92
E. Spaccarotella et al.
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Figure 3. (A) Experimental design to evaluate the functional role of miR-17~92 cluster expression in the TS-SUP-M2 S3S cell line, after STAT3
KD by doxycycline treatment. (B) miR-19a expression levels in TS-SUP-M2 S3S cells transduced with lentiviral particles expressing the indicat-
ed miRNA, as detected by RT-qPCR 4 days after infection. (C) STAT3 and phosho-STAT3 expression in TS-SUP-M2 S3S cells 8 days after doxy-
cycline treatment detected by western blot analysis with the indicated antibodies. (D) Apoptosis analysis in TS-SUP-M2 S3S cells expressing
the indicated miRNA at different time points after induction of STAT3 KD by doxycycline. Analysis was performed by TMRM staining-flow cytom-
etry. These findings are representative of three independent experiments. (E) Tumor growth curves of TS-SUP-M2 S3S cells injected into NSG
mice in the absence (-) or presence (+) of doxycycline. TS-SUP-M2 S3S cells untransduced (UTR) or transduced with miR-17~92 cluster (17-92)
were injected subcutaneously into eight NSG mice. Two weeks after cell injection, six mice of each group were treated with 0.1 mg/mL doxy-
cycline to induce STAT3 KD (+), and two mice remained untreated (-). Tumor growth was monitored over time by determining the volume of
tumor masses. Error bars indicate standard deviation. (F) miR-19a expression levels in mice tumors over-expressing the indicated miRNA after
sacrifice of the animals, as determined by RT-qPCR. UTR: untransduced cells; EV: empty vector; 17~92: miR-17~92 cluster; 17~92 inv: miR-
17~92 cluster antisense.
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over-expression was confirmed by quantification of miR-
19a after tumor excision (Figure 3F). Overall, these find-
ings support the notion that the miR-17~92 cluster could
sustain the oncogenic properties of STAT3 in ALK+ ALCL. 
Expression of the microRNA-17~92 cluster sustains 
proliferation and survival of STAT3-depleted 
anaplastic large cell lymphoma cells 
We have previously demonstrated that conditional
STAT3 KD in ALK+ ALCL cells is coupled to a G0/G1 cell-
cycle arrest, followed by apoptosis.10 We, therefore, asked
whether forced miR-17~92 expression could complement
either one or both processes. Cell cycle analysis of STAT3-
depleted TS-SUP-M2 S3S cells (5 days after doxycycline
treatment) indicated that lentiviral transduction of the
miR-17~92 cluster specifically increased the proportion of
cells in S-phase and decreased those in G0/G1, as com-
pared to controls cells transduced with empty vector, miR
34a, or 17~92inv (Figure 4A). In contrast, miR-17~92
transduction did not significantly affect the cell cycle or
survival of highly-proliferating TS-SUP-M2 S3S cells
expressing normal levels of STAT3 (Online Supplementary
Figure S7). Consistent with these findings, western blot-
ting analysis revealed that miR-17~92 cluster over-expres-
sion attenuated cyclin A, cyclin B1 and cyclin D3 down-
regulation induced by STAT3 KD (Figure 4B). Moreover,
determination of the DNA content confirmed that expres-
sion of the miR-17~92 cluster significantly protected
STAT3-depleted ALCL cells from apoptosis, as shown by
the reduced fraction of hypodiploid cells (~20%) com-
pared to controls (~50%), 9 days after doxycycline treat-
ment (Figure 4C). Lower levels of apoptosis were associat-
ed with reduced activation of known apoptotic effectors,
such as caspase 3 and caspase 7, as well as decreased
cleavage of the caspases substrate poly (ADP ribose) poly-
merase 1 (PARP1). Since the induction of apoptosis relies
on a fine balance between pro- and anti-apoptotic pro-
teins, we evaluated the effects of miR-17~92 on the level
miR-17~92 cluster sustains the ALCL phenotype
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Figure 4. (A) Cell cycle analysis of TS-SUP-M2 S3S cells expressing the indicated miRNA 5 days after doxycycline treatment. Cells expressing
miR-17~92 cluster displayed reduced G0/G1 arrest and increased S-phase as compared to control cells and cells transduced with the indicat-
ed lentiviral particles. Cell cycle was analyzed by propidium iodide staining-flow cytometry. These findings are representative of three inde-
pendent experiments. (B) Western blot analysis of the experiment described above revealed that cells expressing the miR-17~92 cluster
showed increased levels of cyclin A, B1 and D3 following STAT3 KD as compared to control cells. (C) TS-SUP-M2 S3S cells expressing the miR-
17~92 cluster undergo reduced apoptosis as compared to control cells. Propidium iodide staining analysis was performed at day 9 after induc-
tion with doxycycline. The sub-G0/G1 fraction was used to quantify apoptotic cells. These findings are representative of three independent
experiments. (D) Western blot analysis of the experiment descibed above (C) revealed that miR-17~92 over-expressing cells displayed lower
levels of activated caspase 3 and caspase 7, processed PARP, BIM and higher levels of IAP1 protein. Asterisk (*) indicates unspecific band for
IAP1.
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of several survival regulating proteins. Among these, cellu-
lar inhibitor-of-apoptosis protein 1 (IAP1) was consider-
ably down-regulated by STAT3 KD. In contrast, IAP2 and
XIAP, protein levels remained unchanged (Figure 4D, and
data not shown). According to the above-described anti-
apoptotic activity of the miR-17~92 cluster, its forced
expression attenuated IAP1 down-regulation induced by
STAT3 KD. However, IAP1 modulation could not be
explained via a direct effect of miR-17~92. We, therefore,
searched among validated miR-17~92 cluster targets,34
those potentially implicated in cell death. Western blotting
analysis of p21, PTEN, pRB2, E2F1, and BIM proteins indi-
cated that the forced expression of the miR-17~92 cluster
induced the exclusive down-modulation of BIM, both in
basal and STAT3 KD conditions (Figure 4D, and data not
shown). These findings suggest that the miR-17~92 cluster
might mediate resistance to STAT3 KD by targeting BIM.  
Genes modulated by forced expression of the miR-17~92
cluster in anaplastic large cell lymphoma cells 
The oncogenic nature of miR-17~92 is supported by the
identification of several targets with key roles both in cell
cycle control and cell death.35 In this scenario, we asked
whether miR-17~92-mediated rescue of STAT3 KD in
ALCL cells could occur through mechanisms additional to
BIM regulation. To identify potential miR-17~92 targets in
ALCL cells, we performed gene expression profiling exper-
iments in the ALK+ ALCL cell line TS-SUP-M2, following
inducible STAT3 KD. Samples from two independent repli-
cates were processed and hybridized to HT-12 v4 bead
chips (Illumina), which target more than 47,000 human
transcripts. Experiments were carried out 96 h after doxycy-
cline or mock treatment. As controls, we used TS-SUP-M2
cells not transduced (UTR) or transduced with the antisense
construct (17~92inv). Using as selection criteria fold-change
>2, P<0.001, detection >0.99, microarray data analysis iden-
tified 87 genes modulated by miR-17~92 in STAT3 KD con-
ditions (Online Supplementary Table S2). Among these, the
expression of several known miR-17~92 targets,36-38 such as
hypoxia-inducible factor 1α (HIF1α), retinoblastoma-like 2
(RBL2/p130), and the transforming growth factor β receptor
II (TGFβR2) genes, was modified as expected (Figure 5).
Validations performed by RT-qPCR analyses in independ-
ent experiments indicated that TGFβR2 expression was sig-
nificantly increased by STAT3 KD, and that the miR-17~92
cluster down-regulates TGFβR2 transcripts in both the pres-
ence and absence of STAT3 expression (Figure 5C and
Online Supplementary Figure S8). 
Discussion
It is known that target therapies will inevitably boost
the development of acquired resistance. With no excep-
tion, the treatment of ALK+ ALCL with ALK inhibitor(s)
also results in the selection of tumor cells unresponsive to
the drug(s).17 The lesson learned from treatments with sev-
eral tyrosine kinase inhibitors and, specifically, from ALK
inhibitors in non-small cell lung carcinomas is that resist-
ance could come from either secondary mutations in the
ALK tyrosine kinase domain,39 ALK gene amplification,
aberrant activation of alternative receptors by amplifica-
tion,16,40 or by paracrine stimulation.41 To design foresight-
ed therapeutic approaches for ALK+ ALCL patients, we
believe that it may be critical to unravel ALK signaling in
specific pathological contexts. Since ALK oncogenic prop-
erties rely on the constitutive activation of multiple path-
ways, it is reasonable to envisage combination therapies
associating conventional drugs with compounds targeting
multiple effectors of ALK signaling. Toward this end,
members of the RAS/ERK, PI3K/mTOR, and JAK/STAT3
pathways are the most promising targets for innovative
therapeutic strategies in ALK+ ALCL patients.6,42,43 Among
these, the vital role of STAT3 demonstrated in ALK+ ALCL
models is well established.9,10 The STAT3 KD phenotype
of ALK+ ALCL cells is associated with reproducible modu-
lation of a large number of genes (~1500), suggesting that
STAT3 signaling leads to concomitant activation of multi-
ple targets.10 Preliminary data from a functional screening
of STAT3-regulated genes in ALK+ cell lines indicate that,
with rare exceptions, modulation of single genes is not
able to determine a remarkable phenotype (R.P. et al., man-
uscript in preparation). We, therefore, reasoned that an
alternative strategy to interfere with multiple ALK key
pathways was to target critical miRNA. Accordingly, we
performed genome-wide miRNA profiling of ALK+ ALCL
cell lines and identified a series of miRNA modulated by
the activity of STAT3. Among these, we found that forced
expression of the miR-17~92 cluster promotes survival of
ALK+ ALCL cells and partially overcomes STAT3 addiction
in cell lines as well as in a xenograft model. Specifically,
we demonstrated that high expression of the miR-17~92
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Figure 5. Expression of TGFβRII as detected by gene expression profiling at 96 h (left panel), and by RT-qPCR after 8 days of doxycycline treat-
ment (right panel). TS-SUP-M2 S3S cells were transduced with the indicated lentivectors and cultured in the presence (+) or absence (-) of doxy-
cycline (1 mg/mL). Experiments were performed in biological duplicates.
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cluster sustains proliferation and inhibits apoptosis of
STAT3-depleted ALCL cells and found that miR-17~92
over-expression is correlated with the down-regulation of
known targets such as BIM and TGFβRII. The polycistron-
ic miRNA cluster 17~92, originally designated as oncomiR-
1, is one of best-characterized oncogenic miRNA.44 Human
miR-17~92 is located at 13q31.3, a region amplified in sev-
eral hematopoietic malignancies and solid tumors, includ-
ing diffuse B-cell lymphoma, follicular lymphoma, Burkitt’s
lymphoma, and lung carcinoma.45 The first functional evi-
dence to support the oncogenic activity of miR-17~92
came from an in vivo mouse B-cell lymphoma model, in
which enforced expression of miR-17-19b collaborated
with the c-myc oncogene to accelerate B-cell lymphomage-
nesis.46 Since this initial observation, the effects of miR-
17~92 overexpression have been examined in multiple ani-
mal models, human cancers, and cell culture systems for its
ability to regulate a number of cellular processes that favor
malignant transformation. 
The significance of the miR-17~92 cluster in STAT3+
ALCL cell lines is confirmed by its high expression in sys-
temic ALK+ ALCL tissue lesions.24,47 In view of the fact that
the miR-17~92 cluster is modulated by interleukin-6/STAT3
signaling in human endothelial cells through a highly con-
served STAT3-binding site in its promoter,48 we speculate
that an ALK-STAT3-mir17~92 pathway would also play a
critical role in ALK+ ALCL cells. This axis could be particu-
larly relevant in light of the indications that STAT3 mediates
the resistance of lung cancer cells to the MEK inhibitor
AZD6244 through the up-regulation of the miR-17~92 clus-
ter, and consequent block of BIM expression.49 Moreover,
the miR-17~92 cluster has been shown to mediate
chemoresistance and enhance tumor growth through
PI3K/AKT pathway activation also in non-Hodgkin’s lym-
phomas, such as mantle cell lymphoma.28
We, therefore, suggest that the combination of a small
molecule–based inhibitor of ALK with a STAT3 inhibitor or
a miR-17~92 inhibitor may be useful to prevent drug resist-
ance in patients with ALK+ ALCL. Moreover, since many
human cancers rely on constitutive activation of STAT3,
this strategy could be extended to other non-Hodgkin’s
lymphomas and many other human tumors.50 Overall,
these data suggest that the miR17~92 cluster could sustain
the oncogenic properties of STAT3 in T-cell lymphoma, and
that its inhibition might represent an alternative avenue to
interfere with ALK signaling in ALCL.
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